Case IPR2022-00142
`United States Patent No. 8,293,742
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SLAYBACK PHARMA LLC
`
`Petitioner
`v.
`
`EYE THERAPIES LLC
`
`Patent Owner
`
`___________________
`
`Case No. IPR2022-00142
`U.S. Patent No. 8,293,742
`___________________
`
`PETITIONER’S SECOND UPDATED EXHIBIT LIST
`
`
`United States Patent No. 8,293,742
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SLAYBACK PHARMA LLC
`
`Petitioner
`v.
`
`EYE THERAPIES LLC
`
`Patent Owner
`
`___________________
`
`Case No. IPR2022-00142
`U.S. Patent No. 8,293,742
`___________________
`
`PETITIONER’S SECOND UPDATED EXHIBIT LIST
`
`
`
`Case IPR2022-00142
`United States Patent No. 8,293,742
`Petitioner hereby submits a current listing of Petitioner’s Exhibits.
`
`UPDATED EXHIBIT LIST
`
`Exhibit
`1001
`
`1002
`1003
`1004
`
`1006
`
`Description
`U.S. Patent No. 8,293,742 (filed July 27, 2009) (issued Oct. 23,
`2012) (’742 Patent)
`Expert Declaration of Neal A. Sher, M.D. (Sher)
`Expert Declaration of Paul A. Laskar, Ph.D. (Laskar)
`U.S. Patent No. 6,294,553 (filed Feb. 14, 2001) (issued Sep. 25,
`2001) (’553 patent)
`1005 Walters, Thomas R., et al. “A Pilot Study of Life Efficacy and Safety
`of AGN 190342-Lf 0.02% And 0.08% In Patients with Elevated
`Intraocular Pressure.” Association for Research in Vision and
`Ophthalmology, vol. 32, no. 4, 15 Mar. 1991, p. 988 (Walters 1991)
`Norden, Richard A. “Effect of Prophylactic Brimonidine or Bleeding
`Complications and Flap Adherence after Laser in Situ
`Keratomileusis.” Journal of Refractive Surgery, vol. 18, no. 4, 2002,
`pp. 468–471 (Norden 2002)
`U.S. Patent 6,242,442 (filed Dec. 7, 1999) (issued June 5, 2001)
`(’442 patent)
`“ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2%.”
`Physicians’ Desk Reference, 52th ed., Medical Economics Company,
`Inc., 1998, p. 487 (Alphagan® Label 1998)
`53 Fed. Reg. 7076-7093 (Mar. 4, 1988) (Federal Register 1988)
`U.S. Application 12/460,941 filed July 27, 2009, downloaded from
`PAIR (’941 Application)
`U.S. Provisional Application 61/207,481 filed February 12, 2009,
`
`1007
`
`1008
`
`1009
`1010
`
`1011
`
`1
`
`
`
`Case IPR2022-142
`United States Patent No. 8,293,742
`
`1012
`
`1013
`
`1014
`
`1015
`
`downloaded from PAIR (’481 Provisional)
`U.S. Provisional Application 61/203,120 filed December 18, 2008,
`downloaded from PAIR (’120 Provisional)
`U.S. Provisional Application 61/192,777 filed September 22, 2008,
`downloaded from PAIR (’777 Provisional)
`U.S. Provisional Application 61/137,714 filed August 1, 2008,
`downloaded from PAIR (’714 Provisional)
`Timmermans, et al., “Structure-Activity Relationships in Clonidine-
`Like Imidazolines and Related Compounds,” Progress in
`Pharmacology, edited by H. Grobecker et al., vol. 3, No. 1, Gustav
`Fischer Verlag, New York, NY, 1980 (Timmermans 1980)
`
`1016
`
`Griffith, Robert K. “Adrenergics and Adrenergic- Blocking Agents.”
`Burger's Medicinal Chemistry and Drug Discovery, edited by
`Donald J. Abraham, 6th ed., vol. 6, John Wiley & Sons, Inc., New
`York, NY, 2003, pp. 2–37 (Griffith 2003)
`1017 Wickberg-Matsson, Anna, and Ulf Simonsen. “Potent α2A-
`Adrenoceptor–Mediated Vasoconstriction by Brimonidine in Porcine
`Ciliary Arteries.” Investigative Ophthalmology & Visual Science,
`vol. 42, no. 9, Aug. 2001, pp. 2049–2055 (Wikberg 2001)
`Robin, Alan L., and Yochanan Burnstein. “Selectivity of Site of
`Action and Systemic Effects of Topical Alpha Agonists.” Current
`Opinion in Ophthalmology, vol. 9, no. 2, 1998, pp. 30–33 (Robin
`1998)
`Lachkar, Yves, and Surinda Dhanjill. “Effect of Brimonidine
`
`1018
`
`1019
`
`2
`
`
`
`Case IPR2022-142
`United States Patent No. 8,293,742
`
`1020
`
`1022
`
`1023
`
`1021
`
`Tartrate on Ocular Hemodynamic Measurements.” Archives of
`Ophthalmology, vol. 116, no. 12, Dec. 1998, pp. 1591–1594
`(Lachkar 1998)
`Carlsson, Anthony M, et al. “The Effect of Brimonidine Tartrate on
`Retinal Blood Flow in Patients with Ocular Hypertension.” American
`Journal of Ophthalmology, vol. 129, no. 3, Mar. 2000, pp. 297–301
`(Carlsson 2000)
`David, R. “Brimonidine (Alphagan®): A Clinical Profile Four Years
`after Launch.” European Journal of Ophthalmology, vol. 11, no.
`2_suppl, 2001, pp. S72–S77 (David 2001)
`Schuman, Joel S., et al. “A 1-Year Study of Brimonidine Twice
`Daily In Glaucoma and Ocular Hypertension.” Archives of
`Ophthalmology, vol. 115, no. 7, July 1997, pp. 847-852 (Schuman
`1997)
`Scruggs, Jennifer T., et al. “The Teardrop Sign: A Rare
`Dermatological Reaction to Brimonidine.” British Journal of
`Ophthalmology, vol. 84, no. 6, 2000, pp. 671–672 (Scruggs 2000)
`File Wrapper, U.S. Application 12/460,941 filed July 27, 2009,
`downloaded from PAIR
`Pasquali, Theodore A., et al. “Dilute Brimonidine to Improve Patient
`Comfort and Subconjunctival Hemorrhage After Lasik.” Journal of
`Refractive Surgery, vol. 29, no. 7, 2013, pp. 469–475 (Pasquali
`2013)
`1026 Murphy, P. J., et al. “How Red Is a White Eye? Clinical Grading of
`Normal Conjunctival Hyperaemia.” Eye, vol. 21, no. 5, 2006, pp.
`633–638 (Murphy 2007)
`
`1024
`
`1025
`
`3
`
`
`
`Case IPR2022-142
`United States Patent No. 8,293,742
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`Derick, Robert J., et al. “Brimonidine Tartrate.” Ophthalmology, vol.
`104, no. 1, Jan. 1997, pp. 131–136 (Derick 1997)
`Burke, James, et al. “Adrenergic and Imidazoline Receptor-Mediated
`Responses to UK-14,304-18 (Brimonidine) in Rabbits and,
`Monkeys.” The Imidazoline Receptor: Pharmacology, Functions,
`Ligands and Relevance to Biology and Medicine, edited by Donald J.
`Reis, et al., Vol. 763, The New York Academy of Sciences, New
`York, NY, 1995, pp. 78–95. (Burke 1995)
`David, Robert, et al. “Brimonidine in the Prevention of Intraocular
`Pressure Elevation Following Argon Laser Trabeculoplasty,”
`Archives of Ophthalmology, vol. 111, No. 10, Oct. 1993, pp. 1387–
`1390 (David 1993)
`U.S. Patent Application Publication No. 2005/0244463 (filed Apr.
`30, 2004) (published Nov. 3, 2005) (US 2005/0244463)
`United States, Center for Drug Evaluation and Research, and Joanne
`Holmes. NDA 20-613 AlphaganTM (Brimonidine Ophthalmic
`Solution) 0.2% Sterile, vol. 1, U.S. Food and Drug Administration,
`1985, pp. 1–286. (CDER Records 20613)
`Rahman, Mamum Q., et al. “Brimonidine for Glaucoma.” Expert
`Opinion Drug Safety, vol. 9, no. 3, 2010, pp. 483–491 (Rahman
`2010)
`U.S. Patent No. 6,562,873 (filed July 10, 2001) (issued May 13,
`2003) (’873 patent)
`Chien, Du-Shieng, et al. “Corneal and Conjunctival/Scleral
`Penetration of P-Aminoclonidine, AGN 190342, and Clonidine in
`Rabbit Eyes.” Current Eye Research, vol. 9, no. 11, 1990, pp. 1051–
`
`4
`
`
`
`Case IPR2022-142
`United States Patent No. 8,293,742
`
`1035
`
`1036
`
`1037-
`1042
`1043
`
`1044
`
`1059 (Chien 1990)
`Burke, James, and Michal Schwartz. “Preclinical Evaluation of
`Brimonidine.” Survey of Ophthalmology, vol. 41, no. 1, Nov. 1996,
`pp. S9–S18 (Burke 1996)
`Petitioner’s Limitation By Limitation Listing for U.S. Patent No.
`8,293,742
`Not used
`
`Slayback Defendants’ Stipulation to Limit Invalidity Contentions
`[D.I. 18] in Bausch & Lomb, Inc. et al. v. Slayback Pharma LLC et
`al., Civil Action No. 21-16766 (D.N.J.) (Stipulation)
`Declaration of Robert Frederickson III in Support of Motion for Pro
`Hac Vice Admission
`
`Dated: August 5, 2022
`
`Respectfully submitted,
`
`/Linnea P. Cipriano/
`Linnea P. Cipriano
`(Reg. No. 67,729)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 937-2204
`lcipriano@goodwinlaw.com
`
`Counsel for Petitioner Slayback Pharma LLC
`
`5
`
`
`
`Case IPR2022-142
`United States Patent No. 8,293,742
`
`CERTIFICATE OF SERVICE
`
`I, Linnea P. Cipriano, certify that I caused to be served a true and correct
`
`copy of the foregoing PETITIONER’S SECOND UPDATED EXHIBIT LIST
`
`by email, as follows:
`
`
`
`
`
`
`
`
`
`Bryan Diner
`
`bryan.diner@finnegan.com
`
`Justin Hasford
`
`Justin.hasford@finnegan.com
`
`Caitlin O’Connell caitlin.oconnell@finnegan.com
`
`Christina Yang
`
`christina.yang@finnegan.com
`
`Dated: August 5, 2022
`
`/Linnea P. Cipriano/
`Linnea P. Cipriano
`(Reg. No. 67,729)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 937-2204
`lcipriano@goodwinlaw.com
`
`Counsel for Petitioner Slayback Pharma LLC
`
`6
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
